SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 21, 2004
RESPIRONICS, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-16723 | 25-1304989 | ||
| (State or Other Jurisdiction of | (Commission File | (I.R.S. Employer | ||
| Incorporation) | Number) | Identification Number) | ||
| 1010 Murry Ridge Lane | ||||
| Murrysville, Pennsylvania | 15668-8525 | |||
| (Address of Principal | ||||
| Executive Offices) | (Zip Code) |
724-387-5200
(Registrant’s telephone number, including area code)
TABLE OF CONTENTS
Item 9. REGULATION FD DISCLOSURE.
On May 21, 2004, Respironics, Inc. issued a press release announcing that it will make an offer to acquire for cash the issued share capital of Profile Therapeutics plc (London SE symbol: PTP) for 50.9 pence per share or a total of approximately $44.6 million, at the current exchange rate. A copy of the press release is attached hereto as Exhibit 99.
Exhibits
| 99 | Press release, dated May 21, 2004, issued by Respironics, Inc. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RESPIRONICS, INC. | ||||
| By: | /s/ Daniel J. Bevevino | |||
| Daniel J. Bevevino | ||||
| Vice President, and Chief Financial and | ||||
| Principal Accounting Officer | ||||
Dated: May 21, 2004 |
||||
3